INS and diabetes mellitus: However, superior reductions in 6-month fasting insulin in the metformin arm, and in HOMA-IR in both M and MR arms, suggest potential additive benefit with the addition of insulin sensitizing medications in populations with documented insulin elevation and presumed risk for diabetes and metabolic syndrome.